{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T14:38:33Z","timestamp":1786804713918,"version":"build-2736575974"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2020,3,4]],"date-time":"2020-03-04T00:00:00Z","timestamp":1583280000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,3,4]],"date-time":"2020-03-04T00:00:00Z","timestamp":1583280000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100013238","name":"Faculty of Medicine Siriraj Hospital, Mahidol University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013238","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1007\/s00520-020-05380-6","type":"journal-article","created":{"date-parts":[[2020,3,4]],"date-time":"2020-03-04T03:03:07Z","timestamp":1583290987000},"page":"5335-5342","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Randomized, double-blind, placebo-controlled study of aprepitant versus two dosages of olanzapine with ondansetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving high-emetogenic chemotherapy"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4205-6112","authenticated-orcid":false,"given":"Suthinee","family":"Ithimakin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pathra","family":"Theeratrakul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apirom","family":"Laocharoenkiat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akarin","family":"Nimmannit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charuwan","family":"Akewanlop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nopadol","family":"Soparattanapaisarn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sirisopa","family":"Techawattanawanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krittiya","family":"Korphaisarn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pongwut","family":"Danchaivijitr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,4]]},"reference":[{"issue":"4","key":"5380_CR1","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/s00520-011-1162-4","volume":"20","author":"S Ithimakin","year":"2012","unstructured":"Ithimakin S, Runglodvatana K, Nimmannit A, Akewanlop C, Srimuninnimit V, Keerativitayanan N, Soparattanapaisarn N, Laocharoenkeat A (2012) Randomized, double-blinded, placebo-controlled trial of ondansetron plus dexamethasone with or without metoclopramide as antiemetic prophylaxis in patients receiving high-dose cisplatin in medical practice. Support Care cancer 20(4):849\u2013855. https:\/\/doi.org\/10.1007\/s00520-011-1162-4","journal-title":"Support Care cancer"},{"issue":"2","key":"5380_CR2","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s00520-016-3423-8","volume":"25","author":"L Thamlikitkul","year":"2017","unstructured":"Thamlikitkul L, Srimuninnimit V, Akewanlop C, Ithimakin S, Techawathanawanna S, Korphaisarn K, Chantharasamee J, Danchaivijitr P, Soparattanapaisarn N (2017) Efficacy of ginger for prophylaxis of chemotherapy-induced nausea and vomiting in breast cancer patients receiving adriamycin-cyclophosphamide regimen: a randomized, double-blind, placebo-controlled, crossover study. Support Care Cancer 25(2):459\u2013464. https:\/\/doi.org\/10.1007\/s00520-016-3423-8","journal-title":"Support Care Cancer"},{"key":"5380_CR3","doi-asserted-by":"publisher","unstructured":"Vimolchalao V, Sakdejayont S, Wongchanapai P, Sukprakun S, Angspatt P, Thawinwisan W, Chenaksara P, Sriuranpong V, Vinayanuwatikun C, Parinyanitikun N, Poovorawan N, Tanasanvimon S (2019) The efficacy and safety of the addition of olanzapine to ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. https:\/\/doi.org\/10.1007\/s10147-019-01570-3","DOI":"10.1007\/s10147-019-01570-3"},{"issue":"4","key":"5380_CR4","doi-asserted-by":"publisher","first-page":"372","DOI":"10.21037\/apm.2019.08.04","volume":"8","author":"P Tienchaiananda","year":"2019","unstructured":"Tienchaiananda P, Nipondhkit W, Maneenil K, Sa-Nguansai S, Payapwattanawong S, Laohavinij S, Maneechavakajorn J (2019) A randomized, double-blind, placebo-controlled study evaluating the efficacy of combination olanzapine, ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving doxorubicin plus cyclophosphamide. Ann Palliat Med 8(4):372\u2013380. https:\/\/doi.org\/10.21037\/apm.2019.08.04","journal-title":"Ann Palliat Med"},{"issue":"2","key":"5380_CR5","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1007\/s00520-016-3449-y10.1056\/NEJMoa1515725","volume":"375","author":"RM Navari","year":"2016","unstructured":"Navari RM, Qin R, Ruddy KJ, Liu H, Powell SF, Bajaj M, Dietrich L, Biggs D, Lafky JM, Loprinzi CL (2016) Olanzapine for the prevention of chemotherapy-induced nausea and vomiting. N Engl J Med 375(2):134\u2013142. https:\/\/doi.org\/10.1007\/s00520-016-3449-y10.1056\/NEJMoa1515725","journal-title":"N Engl J Med"},{"issue":"1","key":"5380_CR6","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1634\/theoncologist.2017-0378","volume":"25","author":"Y Yang","year":"2017","unstructured":"Yang Y, Fang W, Luo F, Chen X, Ma Y, Zhao Y, Zhan J, Xue C, Hou X, Zhou T, Ma S, Gao F, Huang Y, Chen L, Zhou N, Zhao H, Zhang L, Einhorn LH, Rapoport B, Navari RM, Herrstedt J, Brames MJ (2017) 2016 updated MASCC\/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting. Oncologist 25(1):303\u2013308. https:\/\/doi.org\/10.1634\/theoncologist.2017-0378","journal-title":"Oncologist"},{"issue":"6","key":"5380_CR7","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1111\/ecc.1266810.1093\/annonc\/mdv132","volume":"26","author":"Y Cheng","year":"2015","unstructured":"Cheng Y, Shi JH, Chen ZD, Wang QM, Zhang HL, Hu B, Liu B, Zhang QY, Wu Q, Wang D, Shu YQ, Dong J, Han BH, Wang KM, Dang CX, Li JL, Wang HB, Li BL, Lu JG, Zhang ZH, Chen YX, Roila F, Ruggeri B, Ballatori E, Fatigoni S, Caserta C, Licitra L, Mirabile A, Ionta MT, Massidda B, Cavanna L, Palladino MA, Tocci A, Fava S, Colantonio I, Angelelli L, Ciuffreda L, Fasola G, Zerilli F (2015) Aprepitant versus metoclopramide, both combined with dexamethasone, for the prevention of cisplatin-induced delayed emesis: a randomized, double-blind study. Eur J Cancer Care 26(6):1248\u20131253. https:\/\/doi.org\/10.1111\/ecc.1266810.1093\/annonc\/mdv132","journal-title":"Eur J Cancer Care"},{"issue":"22","key":"5380_CR8","doi-asserted-by":"publisher","first-page":"4112","DOI":"10.1200\/jco.2003.01.095","volume":"21","author":"PJ Hesketh","year":"2003","unstructured":"Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F, de Wit R, Chawla SP, Carides AD, Ianus J, Elmer ME, Evans JK, Beck K, Reines S, Horgan KJ (2003) The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Group. J Clin Oncol 21(22):4112\u20134119. https:\/\/doi.org\/10.1200\/jco.2003.01.095","journal-title":"J Clin Oncol"},{"issue":"12","key":"5380_CR9","doi-asserted-by":"publisher","first-page":"2822","DOI":"10.1200\/jco.2005.09.050","volume":"23","author":"DG Warr","year":"2005","unstructured":"Warr DG, Hesketh PJ, Gralla RJ, Muss HB, Herrstedt J, Eisenberg PD, Raftopoulos H, Grunberg SM, Gabriel M, Rodgers A, Bohidar N, Klinger G, Hustad CM, Horgan KJ, Skobieranda F (2005) Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 23(12):2822\u20132830. https:\/\/doi.org\/10.1200\/jco.2005.09.050","journal-title":"J Clin Oncol"},{"issue":"10","key":"5380_CR10","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1016\/j.bbmt.2018.06.005","volume":"24","author":"AB Clemmons","year":"2018","unstructured":"Clemmons AB, Orr J, Andrick B, Gandhi A, Sportes C, DeRemer D (2018) Randomized, placebo-controlled, phase III trial of fosaprepitant, ondansetron, dexamethasone (FOND) versus FOND plus olanzapine (FOND-O) for the prevention of chemotherapy-induced nausea and vomiting in patients with hematologic malignancies receiving highly emetogenic chemotherapy and hematopoietic cell transplantation regimens: the FOND-O Trial. Biol Blood Marrow Transplant 24(10):2065\u20132071. https:\/\/doi.org\/10.1016\/j.bbmt.2018.06.005","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"5380_CR11","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1093\/jjco\/hyy114","volume":"48","author":"H Hashimoto","year":"2018","unstructured":"Hashimoto H, Abe M, Yanai T, Yamaguchi T, Zenda S, Uchitomi Y, Fukuda H, Mori M, Iwasa S, Yamamoto N, Ohe Y (2018) Study protocol for J-SUPPORT 1604 (J-FORCE): a randomized, double blind, placebo-controlled phase III study evaluating olanzapine (5 mg) plus standard triple antiemetic therapy for prevention of chemotherapy induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy. Jpn J Clin Oncol 48(10):950\u2013952. https:\/\/doi.org\/10.1093\/jjco\/hyy114","journal-title":"Jpn J Clin Oncol"},{"issue":"5","key":"5380_CR12","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.suponc.2011.05.002","volume":"9","author":"RM Navari","year":"2011","unstructured":"Navari RM, Gray SE, Kerr AC (2011) Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. J Support Oncol 9(5):188\u2013195. https:\/\/doi.org\/10.1016\/j.suponc.2011.05.002","journal-title":"J Support Oncol"},{"issue":"5","key":"5380_CR13","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1634\/theoncologist.2017-0378","volume":"23","author":"Z Zhang","year":"2018","unstructured":"Zhang Z, Zhang Y, Chen G (2018) Olanzapine-based triple regimens versus neurokinin-1 receptor antagonist-based triple regimens in preventing chemotherapy-induced nausea and vomiting associated with highly emetogenic chemotherapy: a network meta-analysis. Oncologist 23(5):603\u2013616. https:\/\/doi.org\/10.1634\/theoncologist.2017-0378","journal-title":"Oncologist"},{"issue":"8","key":"5380_CR14","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1007\/s00520-003-0482-4","volume":"11","author":"AR Martin","year":"2003","unstructured":"Martin AR, Pearson JD, Cai B, Elmer M, Horgan K, Lindley C (2003) Assessing the impact of chemotherapy-induced nausea and vomiting on patients\u2019 daily lives: a modified version of the Functional Living Index-Emesis (FLIE) with 5-day recall. Support Care Cancer 11(8):522\u2013527. https:\/\/doi.org\/10.1007\/s00520-003-0482-4","journal-title":"Support Care Cancer"},{"issue":"6","key":"5380_CR15","doi-asserted-by":"publisher","first-page":"451","DOI":"10.4103\/ijp.IJP_846_16","volume":"49","author":"G Shivaprakash","year":"2017","unstructured":"Shivaprakash G, Udupa KS, Sarayu V, Thomas J, Gupta V, Pallavi LC, Pemminati S (2017) Olanzapine versus aprepitant for the prophylaxis of chemotherapy-induced nausea and vomiting in breast cancer patients receiving doxorubicin-cyclophosphamide regimen: a prospective, nonrandomized, open-label study. Indian J Pharmacol 49(6):451\u2013457. https:\/\/doi.org\/10.4103\/ijp.IJP_846_16","journal-title":"Indian J Pharmacol"},{"issue":"3","key":"5380_CR16","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1007\/s00520-018-4400-1","volume":"27","author":"S Chanthawong","year":"2019","unstructured":"Chanthawong S, Lim YH, Subongkot S, Chan A, Andalusia R, Ahmad Bustamam RS, Chaiyakunapruk N (2019) Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for managing highly emetogenic chemotherapy in Southeast Asia: a multinational study. Support Care Cancer 27(3):1109\u20131119. https:\/\/doi.org\/10.1007\/s00520-018-4400-1","journal-title":"Support Care Cancer"},{"issue":"2","key":"5380_CR17","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1007\/s10147-017-1200-4","volume":"23","author":"T Yanai","year":"2018","unstructured":"Yanai T, Iwasa S, Hashimoto H, Ohyanagi F, Takiguchi T, Takeda K, Nakao M, Sakai H, Nakayama T, Minato K, Arai T, Suzuki K, Shimada Y, Nagashima K, Terakado H, Yamamoto N (2018) A double-blind randomized phase II dose-finding study of olanzapine 10 mg or 5 mg for the prophylaxis of emesis induced by highly emetogenic cisplatin-based chemotherapy. Int J Clin Oncol 23(2):382\u2013388. https:\/\/doi.org\/10.1007\/s10147-017-1200-4","journal-title":"Int J Clin Oncol"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-020-05380-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-020-05380-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-020-05380-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,4]],"date-time":"2021-03-04T00:56:12Z","timestamp":1614819372000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-020-05380-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,4]]},"references-count":17,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["5380"],"URL":"https:\/\/doi.org\/10.1007\/s00520-020-05380-6","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,4]]},"assertion":[{"value":"23 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The trial protocol was approved by the Siriraj Institutional Review Board. All recruited patients provided written inform consent. The authors have full control of all primary data and allow the journal to review the data if requested.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}